TNFSF11 and cardiomyopathy: The effect of anti-RANKL on dystrophic heart hypertrophy most likely occurs through the upregulation and rescue of SERCA activity, which represents a promising strategy for treating DMD and DMD-induced cardiomyopathy [50].